KKR signed definitive terms Sunday to acquire Integer Holdings for $5.7 billion in cash, removing the Plano-based medical-device manufacturer from public markets after a quiet decade building scale in cardiac rhythm management and neurostimulation components. The transaction values Integer equity at roughly $140 per share, a 27% premium to Friday's close, and marks KKR's third healthcare infrastructure bet north of $5 billion since 2021.

Integer manufactures the subsystems that go inside pacemakers, defibrillators, and spinal-cord stimulators—components sold to Medtronic, Abbott, and Boston Scientific under long-term supply agreements. Revenue reached $1.61 billion in 2023, with 73% of sales tied to cardiac devices and 21% to neuromodulation. The company employs 6,400 people across manufacturing sites in five countries and holds margins near 18% EBITDA, constrained byCapEx cycles tied to clean-room expansions and FDA re-certifications. KKR will finance the purchase through a combination of fund capital and $2.3 billion in committed debt facilities arranged by Goldman Sachs and Bank of America.

The deal solves a valuation problem Integer could not fix as a standalone public entity. Despite consistent revenue growth and operating leverage, the stock traded at 11.2x forward EBITDA before the announcement, a 40% discount to pure-play device manufacturers and a 25% discount to comparable outsourced suppliers. Public investors penalized the dual-segment structure and the exposure to reimbursement risk one layer removed. KKR will collapse that discount by running Integer as a private platform, likely folding in bolt-on suppliers to create a vertically integrated sub-assembly group that can command pricing power with the Big Three device OEMs. The firm has done this twice before—once with Envision Healthcare and again with Heartland Dental—using roll-up strategies to extract margin from fragmented care-delivery and supplier markets.

For allocators, this is a re-rating event with spillover. The 27% premium sets a new floor for publicly traded Tier Two device suppliers, particularly those with long-term OEM contracts and recurring consumable revenue. Companies like Greatbatch competitors and neuromodulation sub-suppliers will see their multiples re-anchor. Family offices with exposure to healthcare services should watch how KKR structures the debt—if they lever Integer above 5.5x EBITDA, it signals confidence that device reimbursement remains stable despite CMS scrutiny on high-cost implants. It also suggests KKR expects M&A activity among the device OEMs themselves, which would increase demand for outsourced manufacturing and create exit optionality within 36 to 48 months.

Operators should track three follow-on events. First, whether Medtronic or Boston Scientific moves to secure alternative suppliers or renegotiates exclusivity terms with Integer within the next 90 days—any such move would signal concern about private-equity ownership affecting delivery timelines. Second, whether KKR installs a new CFO or CEO within six months, which would indicate a shift toward aggressive cost restructuring rather than growth investment. Third, whether KKR announces a tuck-in acquisition of a smaller neuromodulation component supplier within 12 months, which would confirm the roll-up thesis and compress margins for remaining independents.

The deal closes mid-2025, subject to Integer shareholder approval and standard regulatory clearance. KKR's healthcare fund currently holds $19 billion in dry powder.